The trajectory of Sildenafil presents a interesting case for stakeholders in the drug sector. While initially a phenomenal success, producing huge profits, the exclusivity expiration and the subsequent arrival of https://pharma432366.is-blog.com/48728755/the-little-copyright-and-the-pharmaceutical-industry-a-risky-investment